CL2021003525A1 - Ligandos de antígeno de membrana específico de próstata (psma) y sus usos - Google Patents
Ligandos de antígeno de membrana específico de próstata (psma) y sus usosInfo
- Publication number
- CL2021003525A1 CL2021003525A1 CL2021003525A CL2021003525A CL2021003525A1 CL 2021003525 A1 CL2021003525 A1 CL 2021003525A1 CL 2021003525 A CL2021003525 A CL 2021003525A CL 2021003525 A CL2021003525 A CL 2021003525A CL 2021003525 A1 CL2021003525 A1 CL 2021003525A1
- Authority
- CL
- Chile
- Prior art keywords
- psma
- ligands
- prostate
- specific membrane
- membrane antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015 | 2019-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021003525A1 true CL2021003525A1 (es) | 2022-10-21 |
Family
ID=67145647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021003525A CL2021003525A1 (es) | 2019-07-02 | 2021-12-28 | Ligandos de antígeno de membrana específico de próstata (psma) y sus usos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (https=) |
| EP (1) | EP3993837A1 (https=) |
| JP (2) | JP7805170B2 (https=) |
| KR (1) | KR20220044496A (https=) |
| CN (3) | CN114341118A (https=) |
| AR (1) | AR119331A1 (https=) |
| AU (3) | AU2020299974A1 (https=) |
| BR (1) | BR112021026812A2 (https=) |
| CA (1) | CA3144557A1 (https=) |
| CL (1) | CL2021003525A1 (https=) |
| CO (1) | CO2021017708A2 (https=) |
| IL (1) | IL289039B1 (https=) |
| MX (1) | MX2022000136A (https=) |
| PH (1) | PH12021553284A1 (https=) |
| TW (1) | TW202114742A (https=) |
| WO (1) | WO2021001360A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL297323A (en) * | 2020-04-29 | 2022-12-01 | Novartis Ag | Methods for radiological labeling of psma-binding ligands and their kits |
| WO2022108992A1 (en) * | 2020-11-17 | 2022-05-27 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
| CN121604981A (zh) | 2023-07-21 | 2026-03-03 | 诺华公司 | 靶向psma的放射性配体治疗方案 |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2415709A1 (en) | 2000-07-11 | 2003-01-10 | Bml, Inc. | Remedies for bone diseases |
| AU2012294639B2 (en) * | 2011-08-05 | 2017-10-26 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| EP3456700A1 (en) * | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| RS65188B1 (sr) * | 2016-03-22 | 2024-03-29 | Univ Johns Hopkins | Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate |
| CN111032632B (zh) * | 2017-05-30 | 2024-04-12 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| US11813340B2 (en) * | 2018-02-06 | 2023-11-14 | The Johns Hopkins University | PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
| US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 PH PH1/2021/553284A patent/PH12021553284A1/en unknown
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 JP JP2021578240A patent/JP7805170B2/ja active Active
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-06-30 CN CN202510573926.8A patent/CN120441498A/zh active Pending
- 2020-06-30 CN CN202510573851.3A patent/CN120441497A/zh active Pending
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en not_active Ceased
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039B1/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850B2/en active Active
-
2025
- 2025-07-17 JP JP2025120662A patent/JP2025165975A/ja active Pending
- 2025-11-24 AU AU2025271182A patent/AU2025271182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2024200850A1 (en) | 2024-02-29 |
| CO2021017708A2 (es) | 2022-05-20 |
| AU2020299974A1 (en) | 2022-01-27 |
| CN120441498A (zh) | 2025-08-08 |
| JP7805170B2 (ja) | 2026-01-23 |
| IL289039B1 (en) | 2026-03-01 |
| BR112021026812A2 (pt) | 2022-02-22 |
| MX2022000136A (es) | 2022-04-27 |
| PH12021553284A1 (en) | 2022-08-01 |
| AU2024200850B2 (en) | 2025-09-04 |
| AU2025271182A1 (en) | 2025-12-18 |
| US20230226227A1 (en) | 2023-07-20 |
| JP2022538478A (ja) | 2022-09-02 |
| CN114341118A (zh) | 2022-04-12 |
| AR119331A1 (es) | 2021-12-09 |
| IL289039A (en) | 2022-02-01 |
| KR20220044496A (ko) | 2022-04-08 |
| EP3993837A1 (en) | 2022-05-11 |
| JP2025165975A (ja) | 2025-11-05 |
| TW202114742A (zh) | 2021-04-16 |
| WO2021001360A1 (en) | 2021-01-07 |
| CN120441497A (zh) | 2025-08-08 |
| CA3144557A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003525A1 (es) | Ligandos de antígeno de membrana específico de próstata (psma) y sus usos | |
| CO2023004252A2 (es) | Anticuerpos anti-ceacam5 y conjugados y usos de los mismos | |
| CL2022001662A1 (es) | Compuestos y métodos para la degradación dirigida del receptor de andrógenos | |
| MX2020006112A (es) | Complejo que comprende un compuesto orientado a psma vinculado a un radionucleido de plomo o torio. | |
| EA202092306A1 (ru) | Анти-cd24 композиции и их применения | |
| CO2019010943A2 (es) | Anticuerpos de unión a vista a ph ácido | |
| EA201890282A1 (ru) | Улучшенные ингибиторы простатического специфического мембранного антигена (псма), меченные 18f, и их применение в качестве визуализирующих агентов при раке простаты | |
| CL2018003550A1 (es) | Complejos radio-farmacéuticos. | |
| AR110056A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
| CL2017003021A1 (es) | Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. | |
| CL2017000885A1 (es) | Anticuerpos anti-ox40 humanizados y usos de los mismos | |
| MY194484A (en) | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer | |
| MX387596B (es) | Degradadores selectivos del receptor de estrógeno y sus usos. | |
| EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| EA201892802A1 (ru) | Производные аденозина для применения при лечении рака | |
| EA201890894A1 (ru) | Комбинированная терапия | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| PE20200866A1 (es) | Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso | |
| EA201891473A1 (ru) | Комбинированная терапия | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| MX2022000654A (es) | Sistemas fluorescentes para imagenes biologicas y usos de los mismos. | |
| CO2020010043A2 (es) | Marcadores de la enfermedad de farber y usos de estos | |
| EA201791897A1 (ru) | α-МИКРОГЛОБУЛИН ДЛЯ ИСПОЛЬЗОВАНИЯ В ЗАЩИТЕ ПОЧЕК ПРИ РАДИОНУКЛИДНОЙ ТЕРАПИИ | |
| PL427326A1 (pl) | Radiosensybilizator w postaci 5-jodo-4-tio-2'-deoksyurydyny do zastosowania w radioterapii <!--[if gte mso 9]><xml> <o:OfficeDocumentSettings> <o:RelyOnVML/> <o:AllowPNG/> </o:OfficeDocumentSettings> </xml><![endif]--> | |
| MX2025001691A (es) | Radiofarmacos |